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 In this article, we analyzed the studies, that were conducted over the past 
10 years to study the role of the "guard lymph node" in colorectal cancer. 
Researches were studied prospectively as well as retrospectively, in which 
"guard lymph nodes" were defined and was studied the lesion of lymph 
nodes 1, 2 and 3 orders. The purpose of this work is to evaluate and compare 
the results of operations used in collorectal cancer. Results and conclusions 
are presented on the basis of developed and developing countries. 
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Introduction. The wide spread of colorectal cancer, which ranks third, as the cause of deaths 
among all malignant neoplasms, makes the problem of improving the quality of treatment of this 
disease very urgent [1]. The main method of treating colorectal cancer remains surgical, with the 
removal of the colon segment with the tumor and enlarged regional lymphadenectomy. The study of 
the removed lymph nodes has a great practical importance for determining the adequacy of the 
surgical operation and the conduct of adjuvant chemotherapy [2]. The protocols developed by the 
American Ioint Committee on Cancer (AICC) recommend removing at least 12 lymph nodes, but in 
practice half the cases remove less than 12 lymph nodes [3]. 
Because of insufficiently radical surgery, recurrences are required in 30 % of cases, requiring 
repeated interventions [4]. Incomplete and inadequate lymphadenectomy leads to incorrect staging, 
and thus to the choice of inadequate treatment of colorectal cancer. The accuracy of the diagnosis of 
the cancer stage also depends on the quality of the histological examination. The use of 
immunohistochemistry methods increases the accuracy of diagnosis [5]. 
Ideally, all deleleted lymph nodes should be examined using the immunohistochemistry 
technique, but this leads to additional time and cost. 
The concept of the defining role of the "guard lymph node" can fundamentally change the 
approach when choosing the treatment of colorectal cancer [6]. The role of the "guard lymph node" is 
well studied in breast cancer and melanoma [7,8]. It is believed that if there are no cancer cells in the 
remote guard lymph node, it is unlikely that they will be in the lymph nodes of 2 and 3 order. 
Therefore, with early breast cancer, far from always resorting to radical lymphadenectomy [9]. 
The role of the "guard lymph node" in the spread of the cancer process, with colorectal cancer 
has not been studied enough. 
We have analyzed the searches conducted over the past 10 years to study the role of the "guard 
lymph node" in colorectal cancer. Researches were studied prospectively as well as retrospectively, in 
which "guard lymph nodes" were defined and was studied the lesion of lymph nodes 1, 2 and 3 orders. 
In total were studied 108 publications in which the authors investigated the ways of the cancer process 
spreading through the lymphatic system. 
Unfortunately, only 10 multicentre studies have reported data about a sufficiently large 
number of patients [10-19]. Remaining studies are presented with a small number of patients. Most 
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publications are devoted to colon cancer, and only in 33 studies have the searches of lymph node 
involvement in patients with colorectal cancer. 
The number of lymph nodes removed during surgery ranged from 7 to 30, an average is 
15 lymph nodes. 
Different authors used different methods of "guard lymph nodes". In most studies were used 
dyes: patented blue (patent blue V), 1 % of isosulfan blue (lymphazurin), 1 % of methylene blue. In 
2 studies was used radioactive technetium 99 to represent the guard lymph node. In 11 studies were 
used both dyes and radioactive technetium. There is a very small number of works about the use of the 
luminescence method with indiacyanin green [6, 20-26]. 
In 40 studies "guard lymph nodes" were identified during the operation. In the remaining 
studies, lymph nodes were studied in remote preparations. 
The table shows the results of the study of "guard lymph nodes" in a number of publications. 
With the help of existing techniques, "guard lymph nodes" were detected in 92.4 % of patients [10-
19]. However, not all studies received the same results (Table 1). 
It turned out that in studies where comparatively large experience of detection of "guard 
lymph nodes" the percentage of accurate detection was significantly higher (94.6 %) than in studies 
where a small number of patients (less than 100) were analyzed (89.5 %) (p = 0.02). The existing 
methods for determining the "guard lymph nodes" are not sensitive enough: the percentage of 
detection of guard lymph nodes during the operation was significantly lower than their detection in 
remote preparations (89.2 % vs 93.7 %, p = 0.04). 
When detecting lymph nodes during surgery, additional aberrant lymphatic drainage pathways 
were found in 4 % of patients [11-14, 27, 28]. The detection of guard lymph nodes in colon cancer was 
more effective than in rectal cancer (93.1 % vs 83.1 %, p = 0.03). 
The sensitivity of the existing methods of detecting cancerous lesions of the guard lymph 
nodes was only 69.6 % (Table 1), thus, in almost 1/3 of the patients false-negative results were 
determined. This depended on the quality of the histological examination of distant "guard lymph 
nodes". In those cases when the immunohistochemistry methods were additionally used, the accuracy 
of the detection of the cancerous lesion of the guard lymph nodes exceeded 80 % [5, 28, 29-37]. 
It is interesting to note that when the frequency of detection of cancerous lymph node 
involvement in the early stages of the cancer process (T1/T2) was compared with the results with 
advanced cancer (T3/T4), the sensitivity of the techniques was much higher in the early stages (93.4 % 
vs 58.8 %, p = 0.01) [38, 39]. 
The detection of the lesion of "guard lymph nodes" largely depends on the experience of 
researchers. With a large experience in the definition of "guard lymph nodes", the incidence of their 
cancerous lesion was significantly higher than in the authors who did not have much experience 
(85.6 % vs 66.4 %, p <0.01). 
What does give the detection of guard lymph nodes in patients with colorectal cancer? 
Unfortunately, at present, the detection of the lesion of guard lymph nodes in colorectal cancer does 
not affect the volume of the operation, in contrast to breast cancer. Standardly for early cancer and for 
advanced forms of cancer T3/T4 performed approximately the same volume of operations. At the 
same time, a detailed study of the incidence of cancer of various lymph nodes allows to better 
understand the spread of cancer cells in colorectal cancer. Recently, Japanese researchers have created 
a fairly detailed map of the lesion of lymph nodes of various orders in colorectal cancer. The research 
conducted by English oncologists confirmed the importance of such mapping [6]. 
At the present time accumulates the actual material that allows to understand which lymph nodes 
are affected most often and where to look for them. Methods for intraoperative detection of "guard 
lymph nodes" using indicyanin green (YCG) and luminescence endoscopy are being improved [24-28]. 
"Guard lymph nodes," as shown by studies conducted by English oncologists [6], can be 
localized in the first and second order lymph nodes (D1 and D2), which allows to justify the resection 
of the affected bowel area, with the mesentery site where D2 lymph nodes are located.  
The relatively low sensitivity of the existing methods for detecting the early lesion of "guard 
lymph nodes" is apparently due to the insufficient number of clinical studies. In early T1/T2 cancer, the 
sensitivity of the techniques for detecting "guard lymph nodes" is significantly higher than with the 
advanced forms of T3/T4 cancer. A number of researchers proposed a combination of a luminescent 
method using indicyanin green (YCG) with radioactive technetium (Tc99), which significantly improved 
the technique of detecting "guard lymph nodes" for cancer head and neck, and urogenital cancer [40]. 
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Table 1. Results of studies of guard lymphatic nodes in patients with colorectal cancer. 
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Ceranic 45 No data No data methylene blue 1,7 14 19 5 22 
Finan 58 0 58 isosulfan blue 2,2 15 27 7 0 
Sommariva 69 54 15 patented blue 5 12 46 9 12 
Dragan 60 60 0 isosulfan blue 4,1 32 26 0 26,9 
Ivanov 103 48 55 patented blue – 48 52 3 20 
Nordgard 131 131 0 patented blue 4 29 83 13 21,4 
Van der Zaag 132 100 32 patented blue 2 33 11 73 28,8 
Park 69 45 24 methylene blue 2,5 26 27 6 18,5 
Quadros 52 22 30 patented blue technetium 99 3,5 15 16 8 37,5 
Faerden 199 200 0 patented blue 4 32 125 28 29,8 
Lim 120 120 0 isosulfan blue technetium 99 4 29 71 20 11,3 
Kelder 69 69 0 patented blue 2,3 15 49 3 18,4 
Bembenek 315 315 0 patented blue 2 74 156 38 21,3 
Stojadinovic 84 84 0 isosulfan blue 2,7 18 56 8 26,8 
Matter 52 36 12 patented blue 2,7 8 30 10 19,4 
Tiffet 64 49 15 patented blue technetium 99 2,8 12 35 12 5,7 
Van schaik 44 27 17 patented blue 5 26 16 0 30,3 
Liberale 118 71 47 patented blue 2 22 76 14 9,5 
Yagci 47 20 27 patented blue 5,9 16 27 4 14,8 
Thomas 69 63 6 isosulfan blue 2,1 12 38 14 5,3 
Terwisscha 53 56 0 patented blue technetium 99 2,2 12 35 2 14,8 
Saha 500 408 92 isosulfan blue 2,2 186 211 21 26,1 
Khafagy 53 0 53 patented blue – 31 8 8 46 
Codignola 56 52 4 patented blue 2 37 13 6 37,5 
Braat 91 57 34 patented blue 1,8 23 51 8 10,5 
Bell 58 46 12 patented blue 2,9 9 33 14 61 
Bertagnolli 72 72 0 isosulfan blue 2,1 10 42 14 0 
Demirbas 41 25 16 patented blue 3 18 17 2 11,8 
Wong 124 110 12 isosulfan blue 3,8 27 69 24 27,3 
Patten 57 57 0 isosulfan blue technetium 99 3,5 14 31 11 14,3 
Bembenek 48 0 48 technetium 99 3 7 30 9 0 
Bilchik 120 120 18 isosulfan blue technetium 99 1,8 37 73 5 29,5 
Broderick-Villa 50 46 5 isosulfan blue 1,5 10 27 10 – 
Kitagawa 56 19 37 technetium 99 3,5 18 29 4 0 
Paramo 55 55 0 isosulfan blue 1,9 14 30 1 20 
Merrie 25 25 0 patented blue technetium 99 3 4 16 3 25 
Joosten 50 44 6 patented blue 3 8 15 12 13,3 
 
By now it is unclear whether the concept of guard lymph nodes, which is successfully used in 
breast cancer and melanoma, can be used in colorectal cancer. More research are needed, but already 
the experience of using of luminescent laparoscopy with indicyanin green (YCG) shows the 
advisability of identifying "guard lymph nodes" in the early forms of colorectal cancer. The 
identification and careful study of "guard lymph nodes" allows to specify the stage of the process in early 
cancer, which affects the prognosis of the disease and specifies the need for adjuvant chemotherapy. 
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In our clinic, studies have begun to identify "guard lymph nodes" in case of rectal cancer. In 
35 patients with early rectal cancer (T0/T1/T2), we successfully used the surgical technique of 
transanal local excision of mucosal cancer (TEM). However, in all cases of local cancer resection, the 
question of possible lesion of lymph nodes naturally arises. In 12 patients with early cancer of the 
rectum, we used the technique of identifying the guard lymph nodes. For this was injected in a 
submucosal layer at 4 points around the tumor lesion 1 ml of indiacyanin green (YCG), at a 
concentration of 5 mg/ml. In 10-15 minutes after the drug was administered, patients underwent 
laparoscopy. Carefully examined the small pelvis in ordinary and infrared light (Scharz laparoscope). 
Lymphatic vessels and "guard lymph nodes" were colored green and well identified. Were performed 
dissection and removal of colored lymph nodes. The removed lymph nodes were subjected to urgent 
histological examination. In 2 cases of 12 (8 %) in the lymph nodes were found cancer cells. These 
patients underwent laparoscopic surgery - low rectal resection with removal of mesorectum. 
Under observation for 6-24 months in all 12 patients was not detected any recurrence of cancer in all case. 
Conclusions. Thereby, the identification of "guard lymph nodes" in colorectal cancer has an 
important prognostic value. Perhaps later, in improving the methods for detecting "guard lymph 
nodes," it will be possible to trace more detail the spread of cancer cells through lymphatic vessels and 
create a more detailed map of lymph node involvement in colorectal cancer. 
All this will change the tactics of treating early cancer of the rectum and colon. 
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